Lever
Lifestyle
- Regular monitoring for high-risk individuals
- Stress management
- Regular medical check-ups
Blutwerte · Marker
CA-125
Cancer Antigen 125 · CA125
Tumormarker & Screening
- Einheit:
- U/mL
CA-125 measures the level of a glycoprotein antigen in the blood, associated with certain malignancies and other conditions.
Reference Ranges
Reference
0–35U/mL
0
35
LowNormalHigh
Reference
Unit · U/mLLevels can be influenced by menstrual cycle, pregnancy, and benign conditions.
Overview
Übersicht
Cancer Antigen 125 (CA-125) is a glycoprotein often used as a biomarker in the detection and management of ovarian cancer. It is primarily measured in the blood and is associated with the presence of certain types of cancerous and non-cancerous conditions. Researchers have found that CA-125 is not only elevated in ovarian cancer but also in other conditions such as endometriosis, liver disease, and heart failure, which limits its specificity as a cancer marker. Clinically, CA-125 is significant in monitoring the progression and treatment response in ovarian cancer patients. Elevated levels can indicate the presence of malignancy, while decreasing levels may suggest a positive response to treatment. However, its role in early-stage ovarian cancer screening is limited due to low specificity. In the context of athletic performance and biohacking, CA-125 is not directly relevant, as it does not correlate with physical performance or longevity. However, its emerging role in heart failure management may interest those monitoring cardiovascular health. Researchers observed that CA-125 levels can be influenced by various factors, including menstrual cycle, pregnancy, and benign conditions, which can confound its interpretation. Time-of-day and fasting do not significantly affect CA-125 levels, making it a convenient marker for serial monitoring.
Klinische Bedeutung
Elevated CA-125 levels are often associated with ovarian cancer and can indicate disease progression or recurrence. However, elevated levels can also occur in benign conditions, reducing its specificity.
Dynamics
Trend Interpretation
Rising Values
Progressively rising CA-125 levels may suggest cancer progression or recurrence; re-test in 4 weeks if elevated.
Falling Values
Falling levels often indicate a positive response to treatment.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Ovarian cancer
- Endometriosis
- Liver disease
- Heart failure
- Pregnancy
- Menstruation
Cause
Low Levels
- Effective cancer treatment
- Surgical removal of tumor
- Remission
- Low baseline levels
- Non-cancerous health
Protocol
How to Optimize
Lever
Nutrition
- Balanced diet
- High-fiber foods
- Antioxidant-rich foods
Note:
Consult healthcare providers for personalized interventions, especially in cancer management.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Every 6-12 months for high-risk individuals or those under treatment.
Interfering Factors
- Menstrual cycle
- Pregnancy
- Benign gynecological conditions
Related Peptides & Hormones
Brca1
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that the biological role of CA-125 in oncogenesis and its reliability for early-stage ovarian cancer diagnosis remain debated, particularly regarding reference ranges and confounding factors such as benign conditions. Emerging research directions include the integration of CA-125 with novel biomarkers like ctDNA for enhanced early detection. However, researchers have not yet established optimal treatment strategies targeting CA-125 or fully understood its prognostic value in heart failure contexts.
36 Research Publications
2,057
Total Citations
14
Human/RCT
4.0
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer.
ReviewInfluence7.0
356
This study explored the roles of CA-125 in ovarian cancer diagnosis and treatment. Researchers found that CA-125 is not reliable for early-stage diagnosis but is valuable for evaluating treatment efficacy and prognosis. The study emphasizes the need for a better understanding of CA-125's biological role in cancer development.
02Top
#02
Molecular Biomarkers for the Early Detection of Ovarian Cancer.
ReviewInfluence10.0
251
This study examined the role of CA-125 as a biomarker for ovarian cancer detection. Researchers found that while CA-125 is widely used, it has low specificity, leading to the development of multimarker panels to improve diagnostic efficacy. Ongoing research is focused on novel biomarkers for earlier detection of ovarian cancer.
03Top
#03
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
ReviewInfluence7.0
232
Researchers updated guidelines on the clinical use of CA-125 in epithelial ovarian cancer, noting its low sensitivity and specificity for screening. They recommended CA-125 for monitoring treatment response but cautioned against its use as a standalone diagnostic tool.
04
#04
CA125 in ovarian cancer.
ReviewInfluence6.0
219
This study reviewed the clinical use of CA-125 in ovarian cancer screening. Researchers found that while CA-125 is recommended for high-risk women, its sensitivity and specificity are limited. The study also discusses the potential immunological roles of CA-125 and its implications for targeted therapies.
05
#05
Circulating tumor DNA as an early cancer detection tool.
ReviewInfluence2.0
213
This study focused on circulating tumor DNA (ctDNA) as a potential early cancer detection tool. Researchers found that ctDNA could be combined with biomarkers like CA-125 to enhance early detection of cancers without established screening methods. The study highlights the need to overcome challenges before ctDNA can be integrated into healthcare.
06
#06
Clinical potential of proteomics in the diagnosis of ovarian cancer.
ReviewInfluence1.0
118
This study assessed the clinical potential of proteomics in ovarian cancer diagnosis. Researchers found that CA-125 lacks high positive predictive value and is more effective when combined with other tests. The study highlights the promise of proteomic technologies in developing sensitive and specific biomarkers for ovarian cancer.
07
#07
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
HumanInfluence7.0
113
This study evaluated the CA-125 elimination rate constant (KELIM) as a marker of chemosensitivity in ovarian cancer. Researchers found that KELIM is a significant predictor of treatment success and patient prognosis. The study suggests that KELIM could guide decision-making regarding treatment strategies for ovarian cancer patients.
08
#08
Diagnosis of endometriosis.
ReviewInfluence2.0
106
This study examined the challenges in diagnosing endometriosis. Researchers found that serum CA-125 is the best available marker but is only elevated in advanced stages, making it unsuitable for routine screening. The study suggests that a combination of clinical evaluation and imaging techniques is necessary for accurate diagnosis.
09
#09
Cervical Cancer Markers: Epigenetics and microRNAs.
ReviewInfluence4.0
101
Researchers discussed the use of tumor markers like CA-125 in cervical cancer diagnosis but noted the necessity for new markers with higher sensitivity and specificity. They focused on the potential of microRNAs as early biomarkers.
10
#10
BRCA genes: BRCA 1 and BRCA 2.
ReviewInfluence2.0
74
This study reviewed the role of BRCA1 and BRCA2 genes in breast and ovarian cancer. Researchers found that women with BRCA mutations are at increased risk for early-onset cancer and that monitoring includes serum CA-125 levels for ovarian cancer screening. The study emphasizes the importance of genetic testing in cancer risk assessment.
Clinical Trials (17)
17
Total Trials
45,593
Total Enrolled
Transforming Ovarian Cancer Diagnostic Pathways
NCT06129968RECRUITING
Sponsor
Professor Sudha Sundar
Enrollment
34,000
Started
2024
Primary outcome
Sensitivity of ROMA versus CA125 in early stage ovarian cancer
Ovarian Cancer
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
NCT06182917UNKNOWN
Sponsor
West China Second University Hospital
Enrollment
35
Started
2023
Primary outcome
The prognostic value of MRD
Ovarian Cancer
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Sponsor
University Hospital, Linkoeping
Enrollment
40
Started
2022
Primary outcome
Changes in serum levels of CA-125
Epithelial Ovarian Cancer
Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma
NCT03302884UNKNOWN
Sponsor
Institut Paoli-Calmettes
Enrollment
150
Started
2018
Primary outcome
Prognostic value of ctDNA increase for predicting a subsequent clinical, radiological (RECIST v1.1) or biological (CA-125 according to GCIG criteria) diagnosis of disease relapse.
Ovarian Carcinoma
Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125
NCT03004391COMPLETED
Sponsor
Vejle Hospital
Enrollment
25
Started
2017
Primary outcome
Patient uncertainty as to routine measurement of CA125 is measured by combined questionnaires CollaboRATE and Decisional Conflict Scale.
Ovarian Cancer
CA-125 and Severity of Pre-Eclampsia
NCT02704676UNKNOWN
Sponsor
Ain Shams Maternity Hospital
Enrollment
120
Started
2016
Primary outcome
increase serum CA-125 in pre-eclamptic patients
Pre-Eclampsia
Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4
NCT02326064COMPLETED
Sponsor
Centre Hospitalier Departemental Vendee
Enrollment
221
Started
2015
Primary outcome
Tumor Marker CA125
Ovarian TumorOvarian Cancer
The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring
NCT02437760UNKNOWN
Sponsor
E-DA Hospital
Enrollment
200
Started
2015
Primary outcome
The diagnostic Value of the cancer antigen-125 in lung cancer
Lung Cancer
Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass
NCT02109367COMPLETED
Sponsor
Southern Illinois University
Enrollment
52
Started
2014
Primary outcome
HE4 and CA-125 from cul-de-sac wash
Ovarian Cancer
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Sponsor
Eisai Inc.
Enrollment
7
Started
2010
Primary outcome
Number of Participants With Dose Limiting Toxicity (DLT)
Ovarian Cancer
An Open Label Extension Study of the Efficacy of MORAb-003
Sponsor
Morphotek
Enrollment
3
Started
2010
Primary outcome
Duration of Ovarian Tumor Marker (Cancer Antigen 125 [CA125]) Response
Epithelial Ovarian Cancer
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Sponsor
Translational Research in Oncology
Enrollment
61
Started
2009
Primary outcome
Objective Response Rate (ORR) Investigator Assessment: % of Patients in the Group Who Achieve a Complete Response(CR) or Partial Response(PR) According to RECIST Criteria and GCIG CA125 Response Criteria. - Assessments of the Response by the Investigators
Ovarian Neoplasms
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Sponsor
Novo Nordisk A/S
Enrollment
10
Started
2007
Primary outcome
Efficacy of treatment assessed by overall response rate (RR). RR measured and recorded using imaging techniques, CA-125 blood samples and pelvic examination.
CancerOvarian Cancer
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
NCT00899093TERMINATED
Sponsor
Gynecologic Oncology Group
Enrollment
2,500
Started
2007
Primary outcome
CA125 measurements
Fallopian Tube AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaMalignant Ovarian Brenner TumorMalignant Ovarian Clear Cell TumorMalignant Ovarian Endometrioid TumorMalignant Ovarian Mixed Epithelial TumorMalignant Ovarian Mucinous TumorMalignant Ovarian NeoplasmMalignant Ovarian Serous TumorMalignant Ovarian Transitional Cell TumorOvarian AdenocarcinomaPrimary Peritoneal Serous AdenocarcinomaStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Primary Peritoneal CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Primary Peritoneal CancerStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal CancerUndifferentiated Fallopian Tube CarcinomaUndifferentiated Ovarian Carcinoma
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472COMPLETED
Sponsor
National Cancer Institute (NCI)
Enrollment
40
Started
2003
Primary outcome
To determine the prospective incidence of ovarian cancer, breastcancer, primary peritoneal carcinoma, and all cancer among women at increased risk of ovarian cancer, with a special emphasis on womenwho are known BRCA1/2 mutation carriers
Breast CancerOvarian Cancer
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
Sponsor
Genentech, Inc.
Enrollment
129
Started
2003
Primary outcome
Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or Cancer Antigen 125 (CA-125) Changes
Ovarian Cancer
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
NCT00539162RECRUITING
Sponsor
M.D. Anderson Cancer Center
Enrollment
8,000
Started
2001
Primary outcome
Rate of increase in CA 125 levels and other tumor markers over time
Ovarian Cancer
Publication Trend
Research publications about CA-125 over time
6totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer